Uncoupled turnover disrupts mitochondrial quality control in diabetic retinopathy.
Animals
Cell Line
Diabetes Mellitus
Diabetic Retinopathy
/ genetics
Disease Models, Animal
Disease Progression
Female
Humans
Insulin
/ genetics
Male
Mice
Mice, Inbred C57BL
Mitochondria
/ genetics
Mitochondrial Dynamics
/ physiology
Mitophagy
/ genetics
Protein Kinases
/ metabolism
Retina
/ metabolism
Autophagy
Mitochondria
Neuroscience
Ophthalmology
Retinopathy
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
05 12 2019
05 12 2019
Historique:
received:
22
04
2019
accepted:
23
10
2019
pubmed:
30
10
2019
medline:
21
10
2020
entrez:
30
10
2019
Statut:
epublish
Résumé
Mitochondrial quality control (MQC) is crucial for regulating CNS homeostasis, and its disruption has been implicated in the pathogenesis of some of the most common neurodegenerative diseases. In healthy tissues, the maintenance of MQC depends upon an exquisite balance between mitophagy (removal of damaged mitochondria by autophagy) and biogenesis (de novo synthesis of mitochondria). Here, we show that mitophagy is disrupted in diabetic retinopathy (DR) and decoupled from mitochondrial biogenesis during the progression of the disease. Diabetic retinas from human postmortem donors and experimental mice exhibit a net loss of mitochondrial contents during the early stages of the disease process. Using diabetic mitophagy-reporter mice (mitoQC-Ins2Akita) alongside pMitoTimer (a molecular clock to address mitochondrial age dynamics), we demonstrate that mitochondrial loss arose due to an inability of mitochondrial biogenesis to compensate for diabetes-exacerbated mitophagy. However, as diabetes duration increases, Pink1-dependent mitophagy deteriorates, leading to the build-up of mitochondria primed for degradation in DR. Impairment of mitophagy during prolonged diabetes is linked with the development of retinal senescence, a phenotype that blunted hyperglycemia-induced mitophagy in mitoQC primary Müller cells. Our findings suggest that normalizing mitochondrial turnover may preserve MQC and provide therapeutic options for the management of DR-associated complications.
Identifiants
pubmed: 31661466
pii: 129760
doi: 10.1172/jci.insight.129760
pmc: PMC6962019
doi:
pii:
Substances chimiques
Ins2 protein, mouse
0
Insulin
0
Protein Kinases
EC 2.7.-
PTEN-induced putative kinase
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Cochrane Database Syst Rev. 2014 Nov 24;(11):CD011234
pubmed: 25420029
J Cell Biol. 2016 Aug 1;214(3):333-45
pubmed: 27458135
PLoS One. 2014 May 21;9(5):e97970
pubmed: 24848689
Hum Mol Genet. 2011 Mar 1;20(5):867-79
pubmed: 21138942
Transl Vis Sci Technol. 2014 Mar 27;3(2):3
pubmed: 24757593
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2915-2921
pubmed: 28586916
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
pubmed: 7568133
Cell Metab. 2016 Feb 9;23(2):303-14
pubmed: 26686024
Bio Protoc. 2017 Aug 5;7(15):null
pubmed: 28936466
EMBO J. 2017 Jun 14;36(12):1688-1706
pubmed: 28465321
J Neurocytol. 1998 Jun;27(5):329-45
pubmed: 9923979
Int J Cell Biol. 2012;2012:431684
pubmed: 22550491
Eye Brain. 2010;2:99-116
pubmed: 23226947
Cell Metab. 2018 Feb 6;27(2):439-449.e5
pubmed: 29337137
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2653-8
pubmed: 16477035
Cell Death Dis. 2014 Nov 06;5:e1515
pubmed: 25375380
J Exp Med. 2018 May 7;215(5):1287-1299
pubmed: 29622565
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4356-66
pubmed: 27564518
Vision Res. 2017 Oct;139:93-100
pubmed: 28866025
J Cell Sci. 2012 Feb 15;125(Pt 4):795-9
pubmed: 22448035
Eye Vis (Lond). 2015 Sep 30;2:17
pubmed: 26605370
Biochim Biophys Acta. 2015 Nov;1852(11):2474-83
pubmed: 26248057
Immunotherapy. 2011 May;3(5):609-28
pubmed: 21554091
Int J Biochem Cell Biol. 2005 May;37(5):961-76
pubmed: 15743671
Cell Death Dis. 2017 May 11;8(5):e2777
pubmed: 28492550
Exp Eye Res. 2014 Jul;124:1-10
pubmed: 24792588
Front Biosci (Landmark Ed). 2016 Jan 01;21:42-54
pubmed: 26709760
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):864-9
pubmed: 11867609
Diabetes. 1997 May;46(5):887-94
pubmed: 9133560
Surv Ophthalmol. 2002 Dec;47 Suppl 2:S253-62
pubmed: 12507627
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):574-84
pubmed: 23221078
Oxid Med Cell Longev. 2017;2017:8060949
pubmed: 28680532
J Neurosci. 2004 Apr 21;24(16):4070-81
pubmed: 15102922
Free Radic Biol Med. 2011 Nov 15;51(10):1849-60
pubmed: 21911054
Biol Chem. 2012 Jul;393(7):547-64
pubmed: 22944659
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179-83
pubmed: 17896294
Int J Mol Sci. 2017 Aug 28;18(9):null
pubmed: 28846632
Invest Ophthalmol Vis Sci. 2011 Nov 07;52(12):8739-46
pubmed: 22003103
J Biol Chem. 2014 Apr 25;289(17):12005-15
pubmed: 24644293
J Histochem Cytochem. 2010 Feb;58(2):207-18
pubmed: 19875847
Methods. 2000 Oct;22(2):135-47
pubmed: 11020328
Diabetologia. 2016 Oct;59(10):2251-61
pubmed: 27475954
J Cell Sci. 2012 Nov 1;125(Pt 21):4963-71
pubmed: 23277535
Genes Dev. 2009 Apr 1;23(7):784-7
pubmed: 19339684
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16586-91
pubmed: 24067647
Neurochem Int. 2017 Oct;109:202-209
pubmed: 28235551
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2210-8
pubmed: 15914643
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1666-1674
pubmed: 29625493
EBioMedicine. 2017 Jul;21:7-13
pubmed: 28330601
Toxicology. 2017 Nov 1;391:42-53
pubmed: 28789970
EMBO Rep. 2013 Dec;14(12):1127-35
pubmed: 24176932